

Jamjoom Pharmaceuticals Factory Company Voting Results on the Agenda Items of the Extraordinary General Assembly Meeting (First Meeting), that was held on Wednesday 29/12/1446H corresponding to 25/06/2025G.

1. Reviewed and discussed The Board of Directors' report for the fiscal year ended 31/12/2024
2. Approved the Company's Auditor's report for the fiscal year ended 31/12/2024
3. Reviewed and discussed the financial statements for the fiscal year ended 31/12/2024.
4. Approved absolve the liabilities of the members of the Board of Directors for the fiscal year ended 31/12/2024.
5. Approved the remunerations for the members of the Board of Directors, including the expenses allowance, amounting to 2.018.000 Saudi Riyals for the fiscal year ended 31/12/2024.
6. Approved the special remuneration of the Chairman of the Board of Directors in the amount of 1,800,000 SAR for the fiscal year ending on 31/12/2024 in connection with his contribution in developing the image and business of the Company as well as supporting the Company in fulfilling Vision 2030 goals.
7. Approved authorizing the Board of Directors to distribute interim dividends on a semi/quarterly basis for the fiscal year 2025.
8. Approved the Amendment of Article (3-1-2) of the Audit Committee Charter.
9. Non approval on the establishment of an employee long- term incentive program and the authorization of the Board of Directors to determine the terms and conditions of the program, including the offering price for each share allocated to employees, if applicable.
10. Non approval on the company's purchase of one hundred thousand (100,000) shares of its own shares as treasury shares, to be allocated under the Employee long- term incentive program, with the purchase financed through the company's own resources. The Board of Directors shall be authorized to complete the purchase in multiple phases within a maximum period of twelve months (12) from the date of the General Assembly's approval. The purchased shares may be held for a period of up to five (5) years, after which the Company shall follow the procedures and regulations set forth in the applicable laws.
11. Approved the Amendment of Article (3) of the Company's bylaws basic statute related to the (Purposes of the Company).

شركة مساهمة - رأس المال ٧٠٠ مليون ريال، س.ت. ١٥٤٥٩٦-٤٠٣٠

عنوان المصنع : رقم القطعة م . ي : ١ ، المنطقة الصناعية، المرحلة الخامسة، جدة ، ت : ٩٦٦ ١٢ ٦٠٨ ١١١١ ، ف : ٩٦٦ ١٢ ٦٠٨ ١٢٢٢
العنوان البريدي : ٢٢٦٧ ، جدة - ٢١٤٤٢ ، المملكة العربية السعودية، الإدارة : ت : ٩٦٦ ١٢ ٦١٤ ٠٠٩٩ ، ف : ٩٦٦ ١٢ ٦١٤ ٠٠٨٨

Joint Stock Company - Capital SR. 700 Million, C.R. 4030154596

Factory Address: Plot No. ME1 : 3, Phase V, Industrial City, Jeddah, Tel.: + 966 12 608 1111, Fax: + 966 12 608 1222
Postal Address P.O.Box 6267, Jeddah 21442 Saudi Arabia, Administration: Tel.: + 966 12 614 0099, Fax: + 966 12 614 0088
E-mail: jpharma@jamjoompharma.com - Website: www.jamjoompharma.com

شركة مصنع جمجوم للأدوية
Jamjoom Pharmaceuticals Factory Co.



12. Approved the contracts and dealings conducted between the Company and Jamjoom Medicine Store, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board, Mr. Ahmed Yousuf Jamjoom, and Board Members Mr. Mohammed Yousuf Jamjoom, and Mr. Yousuf Mohammed Salah Jamjoom have a direct interest, while the Board Member Ms. Alaa Yousuf Jamjoom has an indirect interest. This involves a sales agreement for pharmaceutical products to be distributed to customers under prevailing commercial terms without preferential benefits, noting that the contractual transaction value for the year 2024 amounted to 754,805,616 Saudi Riyals.
13. Approved the contracts and dealings conducted between the Company and Jamjoom Medicine Store, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board, Mr. Ahmed Yousuf Jamjoom, and Board Members Mr. Mohammed Yousuf Jamjoom and Mr. Yousuf Mohammed Salah Jamjoom have a direct interest, while the Board Member Ms. Alaa Yousuf Jamjoom has an indirect interest. This pertains to the distribution commission based on the distribution agreement for pharmaceutical products to be distributed to customers without preferential benefits, noting that the distribution commission value for the year 2024 amounted to 1,809,068 Saudi Riyals.
14. Approved the contracts and dealings conducted between the Company and Jamjoom Printing Press, in which the Vice Chairman of the Board, Mr. Ahmed Yousuf Jamjoom and Board Member Mr. Yousuf Mohammed Salah Jamjoom have direct interest, while the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom, and Board Members Mr. Mohammed Yousuf Jamjoom, and Ms. Alaa Yousuf Jamjoom have an indirect interest. This includes providing printing services for inserts, packaging and printing on medicine cartons, under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2024 amounted to 10,040,776 Saudi Riyals.
15. Approved the contracts and dealings conducted between the Company and Jamjoom General Agencies, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board, Mr. Ahmed Yousuf Jamjoom, and Board Member Mr. Mohammed Yousuf Jamjoom have a direct interest. While the board members Ms. Alaa Yousuf Jamjoom and Mr. Yousuf Mohammed Salah Jamjoom, have an indirect interest. This involves procuring brand reminder items under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2024 amounted to 976,048 Saudi Riyals.
16. Approved the contracts and dealings conducted between the Company and Tegan Al-Fateh Factory Company Limited, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board, Mr. Ahmed Yousuf Jamjoom, and Board Members Mr. Mohammed Yousuf Jamjoom, Mr. Yousuf Mohammed Salah Jamjoom and Ms. Alaa Yousuf Jamjoom have an indirect interest. This involves an agreement to provide packaging services (cardboard boxes for medicines) under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2024 amounted to 20,061,837 Saudi Riyals.
17. Approved the contracts and dealings conducted between the Company and Dream Sky Travel and Tourism Agency, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom has an indirect interest. This involves providing travel booking services under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2024 amounted to 15,043,109 Saudi Riyals.

شركة مساهمة - رأس المال ٧٠٠ مليون ريال، س.ت. ٤٠٢٠١٥٤٥٩٦

عنوان المصنع : رقم القطعة م . ي . ا : ٣، المنطقة الصناعية، المرحلة الخامسة، جدة ، ت : ٩٦٦ ١٢ ٦٠٨ ١١١١ ، ف : ٩٦٦ ١٢ ٦٠٨ ١٢٢٢
العنوان البريدي : ٢٢٦٧، جدة - ٢٤٤٢، المملكة العربية السعودية، الإدارة : ت : ٩٦٦ ١٢ ٦١٤ ٠٠٩٩ ، ف : ٩٦٦ ١٢ ٦١٤ ٠٠٨٨

Joint Stock Company - Capital SR. 700 Million, C.R. 4030154596

Factory Address: Plot No. ME1 : 3, Phase V, Industrial City, Jeddah, Tel.: + 966 12 608 1111, Fax: + 966 12 608 1222

Postal Address P.O.Box 6267, Jeddah 21442 Saudi Arabia, Administration: Tel.: + 966 12 614 0099, Fax: + 966 12 614 0088

E-mail: jpharma@jamjoompharma.com - Website: www.jamjoompharma.com

شركة مصنع جمجوم للأدوية
Jamjoom Pharmaceuticals Factory Co.



18. Approved the contracts and dealings that took place between the Company and Jamjoom Algeria Lildawa, in which the Chairman of the Board Mr. Mahmoud Yousuf Jamjoom and the Vice Chairman of the Board Mr. Ahmed Yousuf Jamjoom, have a direct interest while the Board Members, Mr. Mohammed Yousuf Jamjoom, Mr. Yousuf Mohammed Salah Jamjoom and Ms. Alaa Yousuf Jamjoom have an indirect interest. These transactions are for the purpose of sale of raw material and semi-finished goods, under prevailing commercial terms and without preferential benefits, noting that the value of transactions for the year 2024 amounted to 6,241,905 Saudi Riyals.
19. Approved the election of Board members from among the candidates for the upcoming term, which will begin on 19/06/2025 and last for 3 years, ending on 18/06/2028 8, The following members have been elected:
 1. Mr. Mahmoud Yousuf Jamjoom- Non-Executive
 2. Dr. Ahmed Yousuf Jamjoom – Executive
 3. Dr. Mohammed Yousuf Jamjoom- Non-Executive
 4. Ms. Alaa Yousuf Jamjoom- Non-Executive
 5. Mr. Noor Ahmad Sherif- Independent
 6. Mr. Waleed Yousuf Jamjoom – Non-Executive
 7. Mr. Faris Ibrahim Algannam– Independent
 8. Benjamin Richard Toogood– Independent
 9. Javed Ghulam Mohammad– Independent

شركة مساهمة - رأس المال ٧٠٠ مليون ريال، س.ت. ٤٠٣٠١٥٤٥٩٦

عنوان المصنع : رقم القطعة م . ي . ١ : ٣، المنطقة الصناعية، المرحلة الخامسة، جدة ، ت : ٩٦٦ ١٢ ٦٠٨ ١١١١ ، ف : ٩٦٦ ١٢ ٦٠٨ ١٢٢٢
العنوان البريدي: ٢٦٦٧، جدة - ٢١٤٤٢، المملكة العربية السعودية، الإدارة : ت : ٩٦٦ ١٢ ٦١٤ ٠٠٩٩ ، ف : ٩٦٦ ١٢ ٦١٤ ٠٠٨٨

Joint Stock Company - Capital SR. 700 Million, C.R. 4030154596

Factory Address: Plot No. ME1 : 3, Phase V, Industrial City, Jeddah, Tel.: + 966 12 608 1111, Fax: + 966 12 608 1222
Postal Address P.O.Box 6267, Jeddah 21442 Saudi Arabia, Administration: Tel.: + 966 12 614 0099, Fax: + 966 12 614 0088
E-mail: jpharma@jamjoompharma.com - Website: www.jamjoompharma.com

شركة مصنع جمجوم للأدوية
Jamjoom Pharmaceuticals Factory Co.

